Cargando…

CDK4/6 inhibitor: from quiescence to senescence

Detalles Bibliográficos
Autores principales:	Yoshida, Akihiro, Diehl, J. Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4675777/ https://www.ncbi.nlm.nih.gov/pubmed/26697514

Ejemplares similares

P53 levels govern the choice between senescence and quiescence
por: Meek, David W.
Publicado: (2010)

MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
por: Kovatcheva, Marta, et al.
Publicado: (2015)

Stress-mediated exit to quiescence restricted by increasing persistence in CDK4/6 activation
por: Yang, Hee Won, et al.
Publicado: (2020)

Senescence as a therapeutically relevant response to CDK4/6 inhibitors
por: Wagner, Verena, et al.
Publicado: (2020)

Unraveling the genomic determinants of response to CDK4/6 inhibitors
por: Litchfield, Lacey M., et al.
Publicado: (2018)

CDK6 Levels Regulate Quiescence Exit in Human Hematopoietic Stem Cells
por: Laurenti, Elisa, et al.
Publicado: (2015)

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma
por: Qie, Shuo, et al.
Publicado: (2019)

SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
por: Yoshida, Akihiro, et al.
Publicado: (2019)

Cellular senescence in the response of HR(+) breast cancer to radiotherapy and CDK4/6 inhibitors
por: Klapp, Vanessa, et al.
Publicado: (2023)

Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases?
por: Schlam, Ilana, et al.
Publicado: (2021)

The transcriptome of CDK4/6 inhibition
por: Knudsen, Erik S., et al.
Publicado: (2017)

From quiescence to proliferation: Cdk oscillations drive the mammalian cell cycle
por: Gérard, Claude, et al.
Publicado: (2012)

Unexpected Outcomes of CDK4/6 Inhibition
por: Choi, Yoon Jong, et al.
Publicado: (2013)

Hypoxia, MTOR and autophagy: Converging on senescence or quiescence
por: Blagosklonny, Mikhail V.
Publicado: (2013)

Inducible deletion of CDK4 and CDK6 – deciphering CDK4/6 inhibitor effects in the hematopoietic system
por: Maurer, Barbara, et al.
Publicado: (2020)

Dormant cancer cells: programmed quiescence, senescence, or both?
por: Truskowski, Kevin, et al.
Publicado: (2023)

321 Impact of CDK4/6 inhibitor-induced cellular senescence on stromal responses to breast cancer
por: Gallanis, Gregory T., et al.
Publicado: (2022)

CDK4/6 inhibition: the late harvest cycle begins
por: Goel, Shom, et al.
Publicado: (2016)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
por: Pandey, Kamal, et al.
Publicado: (2020)

Molecular mechanism of G(1) arrest and cellular senescence induced by LEE011, a novel CDK4/CDK6 inhibitor, in leukemia cells
por: Tao, Yan-Fang, et al.
Publicado: (2017)

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
por: Al-Qasem, Abeer J., et al.
Publicado: (2022)

Predicting clinical benefit from continuation of cyclin dependent kinase (CDK) 4/6 inhibitors beyond progression
por: Foldi, Julia, et al.
Publicado: (2023)

CDK 4/6 inhibitors for the treatment of meningioma
por: Young, Jacob S., et al.
Publicado: (2022)

CDK 4/6 inhibitors for adjuvant therapy in early breast cancer—Do we have a clear winner?
por: Akhade, Amol, et al.
Publicado: (2022)

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
por: Vijayaraghavan, Smruthi, et al.
Publicado: (2017)

Elimination of Proliferating Cells Unmasks the Shift from Senescence to Quiescence Caused by Rapamycin
por: Leontieva, Olga V., et al.
Publicado: (2011)

PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
por: Klein, Mary E., et al.
Publicado: (2018)

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
por: Wu, Xuewei, et al.
Publicado: (2021)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
por: Sun, Ran, et al.
Publicado: (2022)

Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
por: De Angelis, Claudia, et al.
Publicado: (2020)

The p53 inducing drug dosage may determine quiescence or senescence
por: Lane, David P., et al.
Publicado: (2010)

Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2
por: Pack, Lindsey R., et al.
Publicado: (2021)

Battling quiescence for tumor eradication: too good to be true?
por: McCarty, Nami
Publicado: (2018)

Aging during C. elegans L1 quiescence
por: Mata-Cabana, Alejandro, et al.
Publicado: (2020)

CSN5 specifically interacts with CDK2 and controls senescence in a cytoplasmic cyclin E-mediated manner
por: Yoshida, Akihiro, et al.
Publicado: (2013)

The interplay of CDK4 and CDK6 in melanoma
por: Kollmann, Karoline, et al.
Publicado: (2019)

Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy
por: van Aken, Evert S. M., et al.
Publicado: (2021)

CDK6 and p16(INK4A) in lymphoid malignancies
por: Kollmann, Karoline, et al.
Publicado: (2013)

The role of CDK4/6 inhibitors in early breast cancer
por: Gil-Gil, Miguel, et al.
Publicado: (2021)

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC
por: Zhang, Jinmeng, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ktslgpfsd335nrmfdki1bqco2u